Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of neoadjuvant TACE plus tislelizumab versus perioperative SOX in locally advanced gastric adenocarcinoma
ChiCTR2000035665Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab, oxaliplatin and tegafur in gastric adenocarcinoma and gastric cancer (GC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: pathological complete response. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
tislelizumaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2000035665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035665.